🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to researchers.

An International Challenge

Gonorrhoea infections are on the rise worldwide, with data suggesting over 82 million infections per year. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the context of rising global incidence, escalating drug resistance and the very limited available drugs presently on offer.”

Public health authorities are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". A tracking program showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is employed against UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a significant shift in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Outcomes and Global Access

As per results released by a major medical journal, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which involves two antibiotics. The trial enrolled nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have shared hope. The availability of a one-pill regimen such as this is described as a "critical tool" for gonorrhoea control. This is viewed as essential to reduce the burden of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.